Walter M. Stadler to Mechanistic Target of Rapamycin Complex 1
This is a "connection" page, showing publications Walter M. Stadler has written about Mechanistic Target of Rapamycin Complex 1.
Connection Strength
0.050
-
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
Score: 0.050
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.